Vyleesi Real-World Response Rate: What Patients Actually Experience

What the FDA Approval Data Actually Show

Bremelanotide cleared the FDA bar in June 2019 based on two identically designed Phase 3 randomized controlled trials collectively called RECONNECT (Studies 301 and 302, combined N=1,267 premenopausal women with hypoactive sexual desire disorder, HSDD). The coprimary endpoints were change from baseline in the Female Sexual Function Index desire domain (FSFI-D) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 (FSDS-DAO). Both trials met statistical significance on both endpoints [1].

The FDA's own review documents show that roughly 25% of bremelanotide-treated patients achieved the pre-specified responder definition (a meaningful improvement in both desire and distress) compared with approximately 17% on placebo [2]. That 8-percentage-point separation is real but modest. Clinicians who reviewed the approval called the effect size "clinically meaningful for a subset of patients" rather than a broad-population treatment.

How RECONNECT Measured Response

The FSFI desire domain runs from 1.2 to 6.0. Bremelanotide-treated patients gained a mean of 0.5 points more than placebo over the 24-week treatment period. The FSDS-DAO item 13 distress score dropped by a mean 0.3 points more than placebo. Both differences were statistically significant (P<0.001 for desire; P<0.01 for distress) [1].

Those numbers look small in isolation. Sexual desire is difficult to quantify, and a half-point shift on a 5-point subscale can represent a meaningful change in daily experience for a patient who started near the floor of the scale.

The Placebo Response Problem

The placebo arm responded substantially, with roughly 17% of control patients meeting responder criteria. That high placebo rate is common in sexual-function trials and partly reflects expectation, partner dynamics, and the act of paying clinical attention to sexual health. It compresses the apparent drug effect without negating it.

Real-World Response Rates: Reddit and Patient Review Platforms

What Reddit Threads Report

Searches of r/TwoXChromosomes, r/DeadBedrooms, and r/WomensHealth between 2020 and 2024 show a recurring pattern: patients who tolerate the nausea describe moderate-to-strong increases in desire within 60 to 90 minutes of injection, often lasting through the following day. Patients who vomit or experience severe flushing after the first or second dose almost universally discontinue.

A rough read of the sentiment across several hundred posts suggests the effective-responder group in real-world practice may be closer to 20% to 25% of starters, consistent with the trial data once dropout from side effects is factored out. These are not controlled data, but the directional consistency with RECONNECT is notable.

Drugs.com and Trustpilot Ratings

On Drugs.com (approximately 140 ratings as of late 2024), bremelanotide holds a mean rating near 5.8 out of 10. The bifurcation is sharp: roughly a third of reviewers rate it 8 or above, describing meaningful desire restoration, while another third rate it 3 or below and cite nausea, hyperpigmentation, or lack of noticeable effect. The middle third report partial benefit that did not justify continued self-injection.

Trustpilot data for telehealth providers dispensing bremelanotide follow a similar pattern. Positive reviews emphasize the on-demand dosing model (no daily pill required) and psychological reassurance from feeling desire again. Negative reviews focus on the injection burden and gastrointestinal side effects.

A Practical Response-Rate Framework

Based on the RECONNECT trial data and the pattern visible in patient reviews, a three-tier model describes real-world outcomes better than a single percentage:

Tier 1: Clear responders (estimated 20 to 25% of starters). These patients tolerate the injection, experience manageable nausea or none at all, and report a noticeable increase in desire that they describe as motivating for continued use.

Tier 2: Partial responders (estimated 30 to 35% of starters). These patients notice some desire change but find the nausea-to-benefit ratio unfavorable, or find the injection mechanism inconvenient enough to reduce dosing frequency below what produces consistent effect.

Tier 3: Non-responders or discontinuers (estimated 40 to 45% of starters). These patients stop within 1 to 3 doses due to severe nausea, vomiting, flushing, or no perceived benefit. The Phase 3 discontinuation rate for adverse events was 12.4% in the bremelanotide arm versus 0.8% placebo [2].

Bremelanotide's Mechanism and Why It Does Not Work for Everyone

Bremelanotide is a melanocortin receptor agonist. It binds MC1R, MC3R, and MC4R receptors in the central nervous system, with MC4R activity in the hypothalamus thought to drive the pro-desire effect [3]. The drug does not act on estrogen, progesterone, or testosterone pathways directly.

Why Individual Response Varies

MC4R expression and downstream signaling vary across individuals. Patients with lower baseline melanocortin tone, or those whose HSDD has a primary hormonal or structural cause (such as surgically induced menopause or pelvic floor dysfunction), may see less benefit because the melanocortin pathway is not their primary bottleneck [4].

The FDA label specifies that bremelanotide is indicated only for premenopausal women. Its efficacy in postmenopausal women has not been established in controlled trials, and the hormonal milieu of menopause changes central desire circuitry in ways that bremelanotide's mechanism does not address [2].

Cardiovascular Signal

Bremelanotide causes a transient mean blood-pressure increase of approximately 2 mmHg systolic within 12 hours of injection, with individual spikes reaching 6 mmHg or more in some patients [2]. The FDA therefore contraindicated use in patients with known cardiovascular disease. This contraindication removes a meaningful fraction of women who might otherwise be candidates, particularly those over 40 with hypertension or metabolic syndrome.

Comparing Bremelanotide to Flibanserin (Addyi)

Flibanserin (Addyi), approved in August 2015, is the only other FDA-approved treatment for HSDD in premenopausal women [5]. The two drugs have different mechanisms, different dosing schedules, and different side-effect profiles.

| Feature | Bremelanotide (Vyleesi) | Flibanserin (Addyi) | |---|---|---| | Mechanism | Melanocortin receptor agonist | 5-HT1A agonist / 5-HT2A antagonist | | Dosing schedule | On-demand injection | Daily oral tablet (100 mg qhs) | | Primary side effect | Nausea (40.3%) | Somnolence, dizziness | | Major contraindication | Cardiovascular disease | Alcohol use; CYP3A4 inhibitors | | FDA approval year | 2019 | 2015 | | Responder rate (Phase 3) | ~25% vs. ~17% placebo | ~10% additional satisfying events vs. Placebo |

Neither drug produces large absolute effect sizes. The American College of Obstetricians and Gynecologists (ACOG) notes in its clinical guidance that pharmacotherapy for HSDD should be considered after psychological and relationship factors have been addressed and ideally in combination with sex therapy [6].

Nausea: The Primary Predictor of Discontinuation

Nausea occurred in 40.3% of bremelanotide-treated patients in the pooled RECONNECT data, compared with 1.5% on placebo [1]. Vomiting occurred in 4.9% versus 0.3%. Flushing affected 20.3% of the treated group. These rates are high enough that the FDA required a patient medication guide and recommends that first doses be given in a clinical or supervised setting when feasible.

Strategies That May Reduce Nausea

Some prescribers recommend taking a 25 mg or 50 mg oral ondansetron tablet 30 minutes before the bremelanotide injection. No controlled trial has evaluated this co-administration. The strategy is extrapolated from ondansetron's established use in chemotherapy-induced nausea and relies on the shared 5-HT3 pathway involved in nausea signaling [7].

Injecting bremelanotide into the abdomen rather than the thigh appears to produce slightly slower absorption and may attenuate peak plasma concentration, which could reduce nausea severity. This is pharmacokinetic inference from the prescribing information's Cmax data, not a head-to-head trial finding [2].

Patients who titrate their exposure by injecting 30 minutes (rather than 45 minutes) before activity and lying down for 20 minutes afterward report anecdotally in multiple Reddit threads that nausea episodes are less intense. No published study has examined this approach.

Hyperpigmentation: The Underreported Side Effect

Focal hyperpigmentation of the face, breasts, and gingiva occurred in 1% of RECONNECT participants with repeated dosing [1]. Because melanocortin receptors regulate melanin synthesis through MC1R, systemic agonism can stimulate pigment production. The effect may be permanent in some patients even after discontinuation.

This side effect appears in fewer than 1 in 10 Drugs.com reviews but surfaces in specialist dermatology literature as a case-series concern [8]. Patients with darker baseline skin tones may be at higher risk for noticeable pigmentation changes. Prescribers should document baseline skin appearance and monitor with repeated injections.

Who Is Most Likely to Respond

Several patient characteristics correlate with a higher probability of meaningful response in the RECONNECT data and in mechanistic reasoning:

Characteristics Associated With Better Response

Patients whose HSDD developed gradually in the context of a stable relationship and without a clear hormonal trigger (such as oophorectomy or oral contraceptive initiation) tend to report better outcomes in observational data. This profile suggests central desire circuitry that is intact but downregulated, which is precisely the scenario where MC4R stimulation may restore tone.

Lower baseline nausea sensitivity is the most practical predictor. Patients who tolerate nausea from other causes without intense distress (for instance, those who did not discontinue opioids or chemotherapy due to nausea) are more likely to persist through the first few doses and reach steady exposure.

Characteristics Associated With Lower Response

Surgically menopausal women, women on aromatase inhibitors for breast cancer, and women with pelvic floor disorders causing dyspareunia tend to report lower benefit in online forums and case reports. These groups have biological drivers of low desire that bremelanotide does not address.

Patients with pre-existing cardiovascular disease or uncontrolled hypertension are contraindicated entirely. Patients on antihypertensive therapy who are otherwise well-controlled may still be poor candidates because the transient blood-pressure rise from bremelanotide could destabilize control [2].

Guidelines and Prescribing Context

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that pharmacological treatment for HSDD should target identifiable biological mechanisms and should be combined with psychosexual education [9]. The guideline endorsed bremelanotide as a reasonable option for premenopausal women who have not responded to or cannot tolerate non-pharmacological approaches.

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care consensus in 2019 recommending that clinicians use a validated tool such as the DSDS (Decreased Sexual Desire Screener) to confirm HSDD before initiating bremelanotide or flibanserin [10]. The DSDS takes under five minutes to administer and increases diagnostic accuracy substantially.

ACOG Practice Bulletin No. 213 (2019) states: "For women with HSDD, both flibanserin and bremelanotide are FDA-approved treatment options, and shared decision-making should include a discussion of modest efficacy, side-effect profile, and cost" [6].

Cost and Access Barriers

Bremelanotide carries a list price near $800 to $1,000 per carton (four auto-injectors) without insurance coverage. Most major commercial plans cover it with prior authorization, but Medicare and Medicaid coverage is inconsistent by state. The manufacturer (Palatin Technologies / AMAG Pharmaceuticals, now Cosette Pharmaceuticals) operates a savings program that may reduce out-of-pocket cost to $99 per month for eligible commercially insured patients.

Telehealth platforms have expanded access in states where clinicians can conduct a full HSDD evaluation via video visit. This matters because many primary care providers remain unfamiliar with bremelanotide and hesitate to prescribe it without specialist input.

Practical Injection Guidance

The drug comes as a 1.75 mg/0.75 mL solution in a disposable auto-injector. Injection sites are the abdomen or thigh (not both simultaneously). The auto-injector delivers the dose in approximately three seconds. Used devices should be disposed of in an FDA-cleared sharps container [2].

Patients should not use more than one dose per 24-hour period and should not exceed approximately eight doses per month based on pharmacokinetic modeling that informed the label. There is no published data on outcomes beyond 24 weeks of treatment.